IJR News — today's news from every sideNicole Hardy The back-and-forth on this offering is exactly why retail investors get whiplash. Pick a lane, DSS. IAG Completes €500 Million Buyback ProgramFinance — Sep 11, 2026ICG Enterprise Trust repurchased 15,000 of its own shares at 1,431 pence and now holds 3,159,402 shares in treasury with 60,394,790 shares in issue (excluding treasury), under its long-term buyback authority. International Consolidated Airlines Group completed its second €500 million buyback, bringing total repurchases to €1 billion under a €1.5 billion capital-return plan, with 97,747,488 shares in treasury awaiting cancellation (about 2.12% of issued capital).
Dana Whitfield The Aegon deal is the real story here - if that integration goes smoothly it could actually justify some of this optimism. 
Derek Foss Curious how much of that $75B in AUM is actually deployed vs dry powder waiting for better entry points. 
Dr. David Crean Book Guides Biopharma Leaders on Commercialization — 1dA new book, Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences by Dr. David H. Crean, offers a practical blueprint for biopharma to move from discovery to commercialization by focusing on three core translations—Data to Capital, Discovery to Deal, and Bench to Boardroom—along with Capital Stack Optimization. Aimed at scientist-founders, pre-commercial CEOs, BD executives, and investors, the work promises actionable risk-reduction insights and will be available on Amazon and major bookstores through Cardiff Advisory LLC.
Jared Kim This book seems helpful for scientist founders who struggle turning research into actual funding and governance plans.
